Finsbury Growth & Income Trust — Looking to ‘digital winners’ for outperformance

Finsbury Growth & Income Trust (LSE: FGT)

Last close As at 06/06/2025

GBP9.14

2.00 (0.22%)

Market capitalisation

GBP1,315m

More on this equity

Research: Investment Companies

Finsbury Growth & Income Trust — Looking to ‘digital winners’ for outperformance

Finsbury Growth & Income Trust (FGT) is managed by Nick Train and Madeline Wright at Lindsell Train. They are disappointed by the trust’s performance but have a high degree of confidence in FGT’s concentrated portfolio of high-quality UK-listed companies, which is biased towards ‘digital winners.’ These businesses sell software, services or data analytics to customers across the globe and trade at meaningful discounts to their international peers. The two newest reported additions to FGT’s portfolio are Clarkson (shipbroking) and Intertek Group (testing and assurance); they are both world-class businesses that happen to be listed in London. Clarkson and Intertek Group have outperformed the growth-focused US Nasdaq Composite Index since 2000, but share price pullbacks over the last six to nine months provided attractive buying opportunities.

Melanie Jenner

Written by

Mel Jenner

Director, Investment Trusts

Investment companies

UK equities

6 June 2025

Price 912.00p
Market cap £1,314m
Total assets £1,427m
NAV 990.1p
1At 4 June 2025.
Discount to NAV 7.9%
Current yield 2.1%
Shares in issue 144.1m
Code/ISIN FGT/GB0007816068
Primary exchange LSE
AIC sector UK Equity Income
Financial year end 30 Sep
52-week high/low 962.0p 800.0p
NAV high/low 1,028.0p 865.5p
Net gearing 0.0%
1At 30 April 2025.

Fund objective

Finsbury Growth & Income Trust’s investment objective is to achieve capital and income growth and provide shareholders with a total return above that of the broad UK market index. It invests principally in the securities of companies either listed in the UK or otherwise incorporated, domiciled or having significant business operations within the UK, while up to a maximum of 20% of the portfolio, at the time of acquisition, may be invested in companies not meeting these criteria.

Bull points

  • Very strong long-term absolute and relative performance versus the broad UK market.
  • Disciplined strategy, with the managers investing with a very long-term perspective.
  • The discount is at the wider end of the three-year range, which may offer a favourable entry point.

Bear points

  • FGT has underperformed its benchmark for the last four consecutive years.
  • Key person risk: Train has built up FGT’s long-term record over the last 24+ years.
  • Despite attractive valuations, UK shares remain out of favour with many global investors.

Analyst

Mel Jenner
+44 (0)20 3077 5700

Finsbury Growth & Income Trust is a research client of Edison Investment Research Limited

Pre-recorded version of the May 2025 Frostrow conference presentation

Source: FGT

Why consider FGT?

Train remains upbeat about the prospects for FGT’s portfolio companies and definitely has ‘skin in the game’; his recent purchase has taken his holding to c 5.6m shares, which is c 3.9% of the company and worth more than £50m. The manager cites legendary US investor Warren Buffett, who stated that a way to generate exceptional returns is from having a concentrated portfolio of exceptional businesses. FGT’s highly concentrated portfolio has around 20 names, with the top 10 making up more than 90% of the fund. With a typically low turnover of around 5% per year, portfolio changes are rare; before the recent purchases of Clarkson and Intertek Group, the last additions to the fund were Rightmove in September 2023 and Fevertree Drinks and Experian in early 2020.

FGT’s current 7.9% share price discount to cum-income NAV is wider than its historical averages (range of 2.1% to 7.8% over the last one, three, five and 10 years). This is likely due to an uncertain macroeconomic backdrop and the trust’s performance over the last few years. However, it should be remembered that FGT has outperformed its benchmark by 3.4pp a year since Lindsell Train took over management of the trust in December 2000 until the end of 2024. Between 2001 and 2020 the trust outpaced the UK market in 16 out of 20 years. FGT has also performed well versus its peers over the long term, ranking second out of the 18 funds in the AIC UK Equity Income sector over the last decade. The trust is subject to a continuation vote at the January 2026 AGM.

NOT INTENDED FOR PERSONS IN THE EEA

FGT: Seeking a return to form from its concentrated UK portfolio

The managers’ approach is to invest in high-quality, hard-to-replicate data assets or brands. These are companies with durable or market-leading franchises or data assets offering the potential for significant long-term returns.

Train says that US tariffs should not affect data providers Experian, RELX or the London Stock Exchange Group. These are subscription-based businesses, which along with Rightmove and Sage and FGT’s holdings in two asset managers (Rathbones and Schroders), which all provide services rather than products, make up around 70% of the portfolio. Two consumer companies, Unilever and Diageo, which are product-based, make up more than 20% of the portfolio. Unilever has only 10% of its revenues generated in the US, some of which is manufactured there, so should not be affected by tariffs. However, Diageo generates 50% of its profits in the US, including Mexican tequila and Canadian Whisky, which are world-class brands but may be subject to tariffs. FGT’s two newest holdings Clarkson and Intertek Group are both leading global players in services rather than manufacturing businesses.

H125 results

In the six months to the end of March 2025, FGT’s NAV and share price total returns of +2.1% and +4.2%, respectively, compared with the benchmark’s +4.1% total return. Performance dipped towards the end of the period on concerns about US tariff reforms, which were announced in early April 2025.

During H125, c 22.5m shares were repurchased (c 13.4% of the share base) at a cost of c £197.7m. An 8.8p per share interim dividend was declared, which was in line with H124.

Increased focus on the trust’s ‘digital winners’

While Train is very disappointed by FGT’s performance, evidenced by a current share price that is similar to the level in 2019, he rightly says that what happens going forward is the important thing. The manager likens the trust’s portfolio to a coiled spring, in which he surely has a high level of conviction given his substantial and increasing personal holding.

Train explains that, in recent years, there has been a material shift in FGT’s portfolio. Since 2019, London-listed ‘digital winners’ have increased from 40% to 62%. There has been a conscious reduction in exposure to consumer brands from 49% to 29%, although the manager stresses that he is happy with the remaining consumer companies in the portfolio. Non-UK listed companies made up 18% of the portfolio in 2019 and have now been sold (note that there is an overlap between consumer and non-UK listed stocks, so the 2019 numbers add up to more than 100%). The portfolio is now 100% committed to the UK stock market, due to Train’s frustration about the prolonged period of it being overlooked by global investors, which has led to disappointing returns from UK shares; he notes that investors can buy world-class UK companies in London for a fraction of the valuation of similar businesses listed overseas.

The manager says that for FGT to outperform, because of their high concentration in the fund, the ‘digital winners’ need to outperform, and to provide some context, these companies represent just c 8% of the benchmark. The manager explains that because of changing technology, for example, the growth in AI, having proprietary information makes these companies’ data even more valuable.

Looking at some of the trust’s ‘digital winners’, Experian is a leading data and analytics company, with financial information on c 200m individuals, predominantly in the United States. None of its competitors have such a rich source of data. Clarkson generates more data per day about the $2tn global maritime industry than any other entity. RELX’s acquired LexisNexis business is one of the first in the world to demonstrate profitability from a large language model of professional data. Train quotes FGT’s deputy manager who suggests that investors may be underestimating the acceleration in revenue and earnings growth for London-listed data and software companies as they roll out new products and services to their customers. London Stock Exchange Group’s Q125 revenues exceeded expectations, in part due to new products from its joint venture with Microsoft, while Rightmove’s revenue is accelerating helped by 250m client contacts every single day.

Train highlights that using the US Nasdaq Composite Index as a guide, digital businesses that experience accelerating revenue growth tend to be afforded a higher valuation. The manager hopes this is true for FGT’s holding in Sage. The stock is trading on 5x revenues, which is a lower valuation than those of its peers. In recent meetings with the company, Sage’s management team have said that the business may get to the rule of 40, whereby operating margins plus revenue growth equal 40% or more. If this does happen, Sage deserves a higher valuation, opines Train. The manager says that Sage started to ‘get its act together’ in 2019 and since then has moved up the rankings of the UK’s top 100 index. If its current business momentum continues and Sage becomes one of the largest 10 UK companies, Train comments that there is significant further upside in this stock.

RELX has been in the portfolio for more than 20 years; in 2000, it was the 68th largest UK company, and it is now the fifth. There has been an acceleration in growth in its legal publishing division helped by AI. RELX’s scientific publishing business generates three times the profits of the legal division and AI adoption is much slower; hence, the manager wonders if RELX could end up being the largest company in the UK.

Current portfolio positioning

Top 10 holdings

At the end of April 2025, FGT’s top 10 holdings made up 91.5% of the portfolio, which was a higher concentration compared with 85.1% 12 months earlier; eight positions were common to both periods. The two companies that featured in the trust’s top 10 list at the end of April 2024 were Mondelēz, which is a US-listed stock that exited the portfolio along with FGT’s other non-UK holdings, and Hargreaves Lansdown, which was sold to a private equity buyer in April 2025.

Sector breakdown

FGT retains exposure to just five of the 11 market sectors, so has zero exposure to the other six, which at the end of April 2025 made up a third of the benchmark. Over the 12 months to the end of April, the largest changes were an increase in industrials (+5.3pp) as the managers are building up the Clarkson and Intertek Group positions, and a decrease in consumer staples (-6.5pp), which included the sale of the non-UK listed companies. Versus the benchmark, the trust’s largest active weights were in the consumer sectors, discretionary (+17.9pp) and staples (+10.2pp), and the lack of healthcare stocks (-11.3pp). FGT’s active share at the end of April 2025 was 83.7%; this is a measure of how a fund compares to an index, with 0% representing full index replication and 100% zero commonality.

Performance: Favourable long-term record

FGT is one of the biggest funds within the relatively large AIC UK Equity Income sector. The trust retains its very strong long-term performance record, with its NAV total return ranking second out of 18 funds over the last decade, which is 31.3pp above the sector average. FGT has had broadly in line/above-average total returns over the last one and three years respectively, but underperformance versus the UK market since 2021 has negatively affected its five-year record, with the trust currently at the bottom of the sector rankings.

In terms of valuation, FGT’s discount is wider than the sector average, where four funds are trading at a small premium. The trust has a competitive ongoing charges ratio and no gearing. Unsurprisingly, given its growth focus, FGT has the lowest dividend yield in the sector.

As shown in Exhibit 7, FGT’s relative performance remains volatile. Its NAV is ahead of the benchmark over the last decade and modestly so over the last year. However, the last six months have been difficult. Looking at the performance of the trust’s top 10 holdings in the year to date, shares that have performed well include Rightmove, which has rejected multiple takeover offers from Australian REA Group, and whose business remains strong helped by a robust housing market and a history of innovative new product introductions. Schroders has delivered good results including growth in its wealth management business. RELX’s revenue growth has been supported by its AI-supported products. The standout detractor to FGT’s performance this year is Diageo; its stock has been in a downtrend since the end of 2021. The company is facing a range of headwinds including consumers trading down to cheaper brands and younger generations drinking less alcohol. There are economic pressures in some of the company’s important end markets and, as discussed earlier in the report, Diageo’s business is likely to be negatively affected by US tariffs. Nevertheless, Train highlights the company’s portfolio of high-quality global brands and marketing acumen, such as its recent high-profile Guinness campaign, which led to a significant increase in demand for this beverage. The manager also notes that, despite Diageo’s share price weakness in recent years, it has still managed to outperform the Nasdaq Composite Index since 2000.

Upside/downside analysis

FGT’s cumulative upside/downside capture rates over the last decade are shown below. The trust’s upside capture of 84% suggests that it will underperform by around 15% during periods when the UK market is rising. FGT’s defensive nature is illustrated by its downside capture rate of 71%, which indicates that FGT is likely to outperform by around 30% during periods of UK share price weakness.

General disclaimer and copyright

This report has been commissioned by Finsbury Growth & Income Trust and prepared and issued by Edison, in consideration of a fee payable by Finsbury Growth & Income Trust. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Finsbury Growth & Income Trust

View All

Latest from the Investment Companies sector

View All Investment Companies content

Research: Healthcare

Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential

Following Immix’s update at the 61st annual American Society of Clinical Oncology conference (ASCO 2025), the company hosted a key opinion leader (KOL) event, which showcased the potential of NXC-201 as an effective treatment option to address the unmet need for patients with relapsed/refractory amyloid light chain amyloidosis (r/r ALA). NXC-201 is the only CAR-T therapy in development for ALA, to our knowledge, offering a glimmer of hope to a patient population that currently only has limited treatment options and for which there are no FDA-approved drugs. The KOLs (three US-based physicians) expressed a willingness to treat patients who do not respond to first-line ALA treatment and those ineligible for stem cell transplants with NXC-201, based on the encouraging clinical data to date. The latest clinical update (NEXICART-2 data presented at ASCO 2025) showed a complete response (CR) rate of 70%, with an attractive safety profile, consistent with prior clinical readouts.

Continue Reading
Cancer cells low poly blue

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free